FIELD: medicine.
SUBSTANCE: method involves administering inmmunotherapy with recombinant interferon-α2b in daily dose of 3x106 MU. It is incubated in thermostat during 1 h at 37°C with 100 ml of autoblood and then it is intravenously introduced to a patient during 1-1.5h daily under blood formula control to reach leukocyte content of>4*109 /l, granulocytes >2*109 /l.
EFFECT: eliminated leukopenia and dose-limiting toxicity risk; accelerated treatment course; reduced risk of infectious complications.
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR TREATING HODGKIN LYMPHOMA CASES | 2004 |
|
RU2280452C2 |
METHOD OF NON-HODGKIN'S LYMPHOMAS TREATMENT | 2000 |
|
RU2180594C1 |
ANTIBIOTIC THERAPY METHOD | 2001 |
|
RU2195294C1 |
METHOD FOR TREATMENT OF RELAPSES IN ONCOGYNECOLOGICAL PATIENTS | 2005 |
|
RU2296564C2 |
METHOD TO TREAT MAMMARY GLAND CANCER | 2000 |
|
RU2178294C2 |
METHOD FOR TREATING MAMMALIAN GLAND CARCINOMA | 1998 |
|
RU2158588C2 |
METHOD OF TREATMENT OF PATIENTS WITH BREAST CANCER | 1998 |
|
RU2145239C1 |
METHOD FOR TREATING CEREBRAL METASTASES OF GENERALIZED SKIN MELANOMA | 2005 |
|
RU2286146C1 |
METHOD FOR TREATING MALIGNANT TUMORS | 2001 |
|
RU2210390C2 |
METHOD FOR TREATING NON-HODGKIN'S LYMPHOMAS | 2001 |
|
RU2211695C2 |
Authors
Dates
2005-08-27—Published
2004-01-22—Filed